Cylex ImmuKnow Cell Function Assay

  • Adriana Zeevi
  • John Lunz
Part of the Methods in Molecular Biology book series (MIMB, volume 1034)


The use of immunosuppression in solid organ transplantation is associated with increased morbidity and mortality. Monitoring trough immunosuppression levels alone in transplant recipients is insufficient to gauge the suppression of immune responses. The ImmuKnow Immune Cell Function Assay (Cylex, Inc., Columbia, MD, USA) has been developed to measure the activity of CD4+ T cells as a marker of global immune-competence. The changes in T cell activation were correlated with the relative risk of rejection and infection. However, the most significant utility of the ImmuKnow test, in combination with other clinical parameters, is to identify immune-compromised patients and to help to tailor individualized immunosuppression regimens.

Key words

Solid organ transplants Infection ATP synthesis Immune response 


  1. 1.
    Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M (2003) Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17:77–88PubMedCrossRefGoogle Scholar
  2. 2.
    Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G (2006) Assessing relative risks of infection and rejection: a meta-­analysis using an immune function assay. Transplantation 82:663–668PubMedCrossRefGoogle Scholar
  3. 3.
    Husain S, Raza K, Pilewski JM, Zaldonis D, Crespo M, Toyoda Y (2009) Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 87:1852–1857. doi: 00007890-200906270-00015 [pii] PubMedCrossRefGoogle Scholar
  4. 4.
    Bhorade SM, Janata K, Vigneswaran WT, Alex CG, Garrity ER (2008) Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 27:990–994PubMedCrossRefGoogle Scholar
  5. 5.
    Israeli M, Klein T, Brandhorst G, Oellerich M (2012) Confronting the challenge: individualized immune monitoring after organ transplantation using the cellular immune function assay. Clin Chim Acta 413:1374–1378PubMedCrossRefGoogle Scholar
  6. 6.
    Kobashigawa JA, Kiyosaki KK, Patel JK, Kittleson MM, Kubak BM, Davis SN (2010) Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant 29:504–508PubMedCrossRefGoogle Scholar
  7. 7.
    Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O (2008) Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: insight into the interplay between hepatitis C virus infection and cellular immunity. Liver Transpl 14:1313–1322PubMedCrossRefGoogle Scholar
  8. 8.
    Te HS, Dasgupta KA, Cao D, Satoskar R, Mohanty SR, Reau N (2012) Use of immune function test in monitoring immunosuppression in liver transplant recipients. Clin Transplant 26:826–832PubMedCrossRefGoogle Scholar
  9. 9.
    Batal I, Zeevi A, Heider A, Girnita A, Basu A, Tan H (2008) Measurements of global cell-­mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 129:587–591PubMedCrossRefGoogle Scholar
  10. 10.
    Thai NL, Blisard D, Tom K, Basu A, Smetanka C, Tan H (2006) Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation 82:1649–1652PubMedCrossRefGoogle Scholar
  11. 11.
    Berglund D, Bengtsson M, Biglarnia A, Berglund E, Yamamoto S, von Zur-Muhlen B (2011) Screening of mortality in transplant patients using an assay for immune function. Transpl Immunol 24:246–250PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Adriana Zeevi
    • 1
  • John Lunz
    • 1
  1. 1.University of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations